Price Action to Note: Is Selling InspireMD Inc Here a Winning Strategy?

Price Action to Note: Is Selling InspireMD Inc Here a Winning Strategy?

The stock of InspireMD Inc (NYSEMKT:NSPR) is a huge mover today! About 139,188 shares traded hands. InspireMD Inc (NYSEMKT:NSPR) has declined 82.62% since April 13, 2016 and is downtrending. It has underperformed by 86.55% the S&P500.
The move comes after 8 months negative chart setup for the $3.01 million company. It was reported on Nov, 15 by Barchart.com. We have $2.04 PT which if reached, will make NYSEMKT:NSPR worth $331,100 less.

InspireMD Inc (NYSEMKT:NSPR) Ratings Coverage

Out of 2 analysts covering InspireMD (NYSEMKT:NSPR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. InspireMD has been the topic of 2 analyst reports since January 7, 2016 according to StockzIntelligence Inc. As per Thursday, January 7, the company rating was initiated by Rodman & Renshaw. The firm earned “Buy” rating on Thursday, January 7 by H.C. Wainwright.

According to Zacks Investment Research, “InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company’s initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel.”

More news for InspireMD Inc (NYSEMKT:NSPR) were recently published by: Reuters.com, which released: “BRIEF-Inspiremd Inc received approval to commercialize CGuard embolic prev…” on November 14, 2016. 247Wallst.com‘s article titled: “Why InspireMD More Than Doubled” and published on November 01, 2016 is yet another important article.

NSPR Company Profile

InspireMD, Inc., incorporated on February 29, 2008, is a medical device company. The Firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The Company’s MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet mesh and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company’s MGuard coronary product, MGuard Prime Embolic Protection System (MGuard Prime EPS), is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment